“This changes everything!”
That was the immediate reaction of Bay Area journalist Fred Gardner as he stood in the office of Steep Hill Laboratory in Oakland and eyed a chromatogram showing the unusual cannabinoid content of a hitherto unknown marijuana strain. The year was 2009, and the strain of interest, an oddity called Soma A-Plus, didn’t top the charts for THC (tetrahydrocannabinol), a.k.a. the high-causer, unlike the several thousand other bud samples that Steep Hill had previously tested for California’s medical marijuana dispensaries and growers.
Soma A-Plus was the first of a handful of soon-to-be-discovered strains imbued with a significant amount of cannabidiol (CBD), a compound with intriguing medical properties. One of these strains, Women’s Collective Stinky Purple, tipped the scales at over 10 percent CBD by dry weight, with little THC. This genetic anomaly wasn’t hemp—it was a drug plant, a high-resin, CBD-rich marijuana strain brimming with medicated goo. But anyone who smoked it or consumed it as an edible wouldn’t get high, because CBD isn’t psychoactive. In fact, CBD can actually lessen or neutralize the THC high, depending on how much of each compound is in a given strain or product.
Traditionally, cannabis grown for hashish contained roughly equal amounts of THC and CBD. Starting in the late 1970s, however, cannabis genetics changed as renegade breeders in Northern California catered to the consumer demand for stonier THC-dominant varietals. Consequently, CBD nearly vanished from the grassroots gene pool in the Emerald Triangle, America’s cannabis breadbasket.
When Californians passed Proposition 215, the 1996 ballot measure that legalized cannabis for medical use statewide, few people knew about CBD. It wasn’t on anyone’s radar, except for a small group of scientific pioneers who were probing marijuana’s molecular mechanisms and healing potential. Early studies indicated that CBD had noteworthy anti-inflammatory, anti-tumoral, antipsychotic and anticonvulsant properties, with no known adverse side effects.
Fred Gardner had been covering the CBD science story in O’Shaughnessy’s, the journal of cannabis in clinical practice. In 2010, he and I launched Project CBD, an educational nonprofit that reported on the entire CBD phenomenon: the research, the patients, the doctors, the new strains and products, and the business angles. From the start, we sensed that CBD could be a game-changer for the medical marijuana movement, that it might be the key to liberating marijuana from the confines of the drug-abuse paradigm. How could the pretzel logicians in the Drug Czar’s office justify the ongoing prohibition of CBD-rich cannabis, a safe medicinal substance with no adverse side effects and that doesn’t even get you high?
The advent of CBD-infused products meant that a lot more people—including those who aren’t into getting stoned—would be open to using marijuana for health reasons. Not everyone enjoys the THC high; some folks get edgy and anxious on weed. CBD-rich cannabis could be the answer for those who want to experience marijuana’s health benefits without the buzz. We referred to it as “CBD-rich” (rather than “high-CBD”) cannabis to get away from the stoner connotation. That designation has since been adopted by medical scientists in peer-reviewed publications.
A Tipping Point
The serendipitous rediscovery of CBD in Northern California would eventually upset everyone’s applecart—cops and stoners alike—and usher in a new era of cannabis therapeutics. The crucial tipping point came in the summer of 2013, when CNN broadcast Dr. Sanjay Gupta’s special on medical marijuana, which featured the now-famous case of Charlotte Figi, a young girl from Colorado who suffered from Dravet’s syndrome.
Little Charlotte was having hundreds of epileptic seizures a week, and pharmaceutical medications weren’t helping. Her parents thought they had run out of options, but then they heard about a boy with Dravet’s syndrome in California who responded well to CBD-rich cannabis oil. They found a high-CBD/low-THC strain at a Colorado cannabis dispensary, and it worked like a charm for their daughter, reducing her seizures to a couple a month. That strain is now called Charlotte’s Web in her honor.
Suddenly, the CBD genie was out of the bottle. A national television audience was stunned by what they saw and heard: Marijuana, once slandered as the “assassin of youth,” could save the lives of desperately ill children. And what’s more, kids and grownups didn’t have to get stoned to get better. The idea that it might be possible to access the therapeutic upside of marijuana sans the euphoria or dysphoria produced by THC would prove irresistible to a lot of people after the CNN special.
But along with a growing awareness of cannabidiol as a potential medicine, there has also been a proliferation of misconceptions about CBD-rich cannabis, a remarkable botanical that has befriended humankind since before the written word. Cannabis has a rich history as a source of fiber, food and medicine in many countries going back thousands of years. But our ancient connection with this plant, and our knowledge of its utility as a versatile folk medicine, was broken by marijuana prohibition. Thus, we’ve had to recreate a rapport with cannabis and relearn how to use it for maximum therapeutic benefit.
Some might wonder: Why not just spark a phatty and inhale? That seems to do the trick for a lot of people. Actually, it’s gotten a lot more complicated now that there are potent cannabis-oil extracts with different ratios of THC and CBD to choose from, as well as various ways to administer them. Figuring out how to harness the curative qualities of cannabis is still a work in progress. It’s the driving force behind the great laboratory experiment in democracy known as medical marijuana that’s been unfolding state by state in recent years.
The Big Breakthrough
For a long time, the illegality of marijuana has acted as a deterrent to scientific research in the United States. Ironically, it was President Ronald Reagan who advanced our understanding of the scientific basis of cannabis therapeutics when he escalated and militarized the War on Drugs in the 1980s. The Reagan administration poured tens of millions of dollars into research that would prove once and for all that marijuana damages the brain—or so they thought. After all, this was the “evil weed,” and it was an article of faith within the Drug War establishment that smoking marijuana causes brain damage.
But rather than showing how marijuana harms the brain, the Reagan administration ended up subsidizing a series of studies that culminated in the discovery of the endocannabinoid system, which actually protects the brain when activated by plant cannabinoids like THC and CBD. This major scientific breakthrough opened up whole new vistas in the understanding of human biology and went a long way toward explaining how and why cannabis is such a multifaceted medicine—and why it’s the most popular illicit herb on the planet.
By the mid-1990s, the endocannabinoid system had emerged as a hot topic among scientists around the world, who shared their findings in highly technical, peer-reviewed journals and at annual meetings of the recently formed International Cannabinoid Research Society. There ensued an avalanche of scientific data attesting to the jaw-dropping therapeutic potential of CBD and other cannabis compounds.
A 1998 preclinical study funded by the National Institutes of Health became the basis for a US government patent on the antioxidant and neuroprotective properties of CBD and THC, which were found to limit “neurological damage following ischemic insults, such as stroke and trauma.” Both compounds were described as having “particular application … in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.”
And that’s just for starters when it comes to cannabidiol. Some highlights from the exploding field of cannabis therapeutics:
- Cancer: Scientists at the California Pacific Medical Center showed that CBD reduces breast-cancer-cell proliferation, invasion and metastasis in human-cell-line experiments.
- Diabetes: Israeli researchers reported that CBD “lowers incidence of diabetes in non-obese diabetic mice.”
- Epilepsy: British scientists noted that CBD exerts anticonvulsant effects in animal models of epilepsy.
- Mood disorders: Brazilian investigators explored CBD’s potent antipsychotic and anti-anxiety properties.
- Acne: The Journal of Clinical Investigation reported in 2014 that “CBD has potential as a promising therapeutic agent for the treatment of acne vulgaris.”
- Irregular heartbeat: The British Journal of Pharmacology disclosed in 2010 that CBD suppresses stroke-induced cardiac arrhythmia in animals and reduces the extent of brain damage.
- Stem-cell neurogenesis: German scientists discovered that CBD stimulates the growth of new brain cells in adult mammals.
- Antibacterial: According to a 2008 report in the Journal of Natural Products, published by the American Chemical Society, CBD “showed potent activity against a variety of methicillin-resistant Staph (MRSA) strains.” The World Health Organization has identified antibiotic-resistant bacteria as a major global health crisis.
- Mad-Cow Disease: There is no known cure for mad cow, a deadly infectious brain disease transmitted by misshaped proteins called “prions.” But French scientists reported in the Journal of Neuroscience that “CBD may protect neurons against the multiple molecular and cellular factors involved in the different steps of the neurodegenerative process, which takes place during prion infection.”
And the list goes on and on: rheumatism, PTSD, depression, gut issues, obesity, alcoholism, liver disease …. Extensive preclinical research and mounting anecdotal reports suggest that these and many other conditions may be responsive to CBD-rich remedies.
The Power Couple: CBD and THC
There’s a lot of excitement about cannabidiol—with good reason. Thus far, however, clinical trials that could “prove” CBD’s therapeutic utility have gotten short shrift in the United States because of the War on Drugs. Consequently, most of what scientists know about CBD is based largely on preclinical lab research—animal studies, molecular probes, test-tube experiments and so on—rather than human studies. Some of this research has yielded important insights into the endocannabinoid system and its crucial role in health and disease. But data from animal models are not always applicable to human experience.
Outside the United States, CBD-rich remedies have been subjected to rigorous clinical trials and approved for therapeutic use in more than two dozen countries. Sativex, a sublingual cannabis spray that contains equal amounts of CBD and THC, is available by prescription (though not yet in the US) for treating the neuropathic pain and spasms associated with multiple sclerosis. GW Pharmaceuticals, the British firm that produces Sativex, determined that a combination of CBD and THC is more effective than either compound alone for pain management.
Simply put, CBD and THC are the power couple of cannabis therapeutics; they work best together. CBD and THC amplify each other’s curative qualities by activating different receptors in the brain. This synergistic dynamic is all-important for medical patients. It’s the reason why THC is key to maximizing the therapeutic potential of CBD, and vice versa.
Cannabis-oil concentrates with varying CBD/THC ratios are available in medical marijuana dispensaries, so patients can adjust or eliminate the psychoactive effects to suit their needs. When present in roughly equal amounts, CBD will prolong the THC buzz while lowering the ceiling on THC’s psychoactivity. These days, cannabis patients also have the option of healing without the high by using a CBD product with only a small amount of THC. But a low-THC oil or flower, while not intoxicating, isn’t necessarily the best treatment modality.
One’s sensitivity to THC is a major factor in determining the optimal ratio and dosage of CBD-rich medicine. There’s no single ratio or dose that’s right for everyone. Cannabis therapeutics is personalized medicine; patients may need to experiment, dial in and, if need be, adjust their treatment regimen until they find their own sweet spot with the right balance of CBD and THC. In essence, the goal is to administer consistent, measurable doses of a CBD-rich remedy that includes as much THC as a person is comfortable with.
If you’re lucky enough to live in a state with a robust medical marijuana program, there are lots of possibilities if you want to use CBD-rich cannabis without smoking it. CBD-rich cannabis—like the stony stuff—comes in many non-smokeable forms: edibles, lozenges, beverages, gel caps, sublingual sprays, tinctures, topical ointments, transdermal patches, suppositories and more. But all of these different choices can be confusing, especially for those who are newcomers to cannabis.
Product safety is also a major concern given that the marijuana industry is still largely unregulated. Unfortunately, many cannabis farmers use pesticides and dubious plant-hormone boosters to increase the cannabinoid content and crop yield. Patients should look for CBD-rich products that have been lab-tested and verified as free of mold, pesticides, solvent residues and other contaminants. It’s also better, if possible, to avoid cannabis oil that has been extracted with butane, hexane or other toxic solvents; opt for safer extraction methods, such as food-grade ethanol or supercritical CO2. A high-quality CBD-rich product should include only high-quality ingredients: no corn syrup, trans fats, preservatives or other artificial additives. Products should have clear labels showing the quantity of CBD and THC per dose. And keep in mind that the CBD/THC ratio is not an indication of how much of each compound is actually in the product.
What about CBD oil extracted from industrial hemp? Internet storefronts are peddling unregulated hemp-derived CBD products to all 50 states, despite the fact that cannabidiol has not been approved by the Food and Drug Administration as a dietary supplement. For many people, particularly those living in states where medical marijuana is not yet legal, hemp-derived CBD may be their only practical option for now, even though it’s technically still a Schedule I controlled substance.
The federal government arbitrarily defines hemp—as distinct from marijuana—as a cannabis plant with 0.3 percent THC or less. However, what actually distinguishes hemp from marijuana is the resin content: Hemp is low-resin cannabis, while marijuana is high-resin cannabis. CBD and THC are both contained in the resin. High-resin drug plants include euphoric THC-rich plants and non-euphoric CBD-rich plants, as well as various combinations of both.
This is why low-resin industrial hemp isn’t an optimal source of CBD oil. Hemp fiber is basically useless for extracting CBD, since there is hardly any resin on the stalk. The skimpy foliage of industrial hemp grown for nutritious seed oil (and other uses) maxes out at about 3.5 percent CBD by dry weight, but there’s no CBD or THC in the seeds themselves. Compare this to the ACDC strain, a non-euphoric, high-resin marijuana varietal widely grown in California, which contains 20 percent CBD by dry weight.
The 0.3 percent THC legal limit for industrial hemp is an impractical, scientifically baseless distinction designed to maintain marijuana prohibition. In an effort to circumvent the law, some farmers in Colorado and other states are growing high-resin, CBD-rich marijuana and calling it hemp; they harvest their crop early to minimize the THC content. Growing industrial hemp outside the parameters of strictly implemented, state-sanctioned pilot research is still forbidden by the federal government.
For hemp farmers abroad, CBD paste is typically a byproduct of industrial hemp grown for other purposes. Farmers sell this leftover hemp biomass to businesses that extract CBD oil. It’s not great starter material for making CBD products, because huge amounts of low-resin hemp refuse are required to extract a small amount of CBD. Also, the more plant material one extracts from, the greater the risk of contaminants, because hemp is a “bio-accumulator” that draws toxins from the soil. That’s a great feature for cleaning up poisoned environments—hemp was planted near Chernobyl after the nuclear disaster for this purpose—but it’s exactly what you don’t want in a medicine.
Thus far, CBD commerce proliferates online with little interference from the federal government, other than FDA warning letters that have been sent to several CBD hemp-oil retailers for mislabeling products and making unproven medical claims. (Some “CBD-oil” products tested by the FDA contained little or no CBD.) Even more disconcerting is what’s actually in these items. Many, if not most, CBD hemp-oil vape cartridges contain propylene glycol, a thinning agent that is carcinogenic when overheated and inhaled. Flavoring agents are also ubiquitous in CBD hemp-oil cartridges, yet few of these ingestible food additives have been safety-tested for inhalation. Some are known to be toxic.
You might find serviceable products marketed as CBD hemp oil if you’re willing to take a chance on the vagaries of online meds. It’s something of a crapshoot, but some of these products may provide health benefits. Low-THC cannabis-oil extracts have been a godsend for a number of children with intractable seizure disorders. There are accounts of epileptic kids who experience a near-complete cessation of seizures when they utilize CBD-oil products. But for many other seizure-disorder sufferers, adults as well as children, CBD doesn’t do the trick. It’s not a miracle cure for everyone.
The therapeutic range of CBD hemp oil is significantly limited by the small amount of THC and other cannabinoids contained therein. Many medical marijuana patients have learned through trial and error that augmenting CBD-rich oil by adding some THC—or THCA, the unheated, non-psychoactive form of THC that’s present in raw cannabis flowers and leaves—helps to keep seizures and other symptoms at bay. Low-THC cannabis-oil products don’t work for everyone; this is why people of all ages need access to the full spectrum of whole-plant cannabis remedies, not just low-THC oil.
Molecule Versus Plant
CBD will soon become a single-molecule pharmaceutical. When Epidiolex, an almost-pure CBD anti-seizure remedy developed by GW Pharmaceuticals, gets a green light from the FDA, cannabidiol will join single-molecule THC (Marinol) as a legally available prescription medication. But the cannabis plant itself will remain federally illegal for the foreseeable future. Go figure.
Project CBD recognizes that single-molecule CBD is not the same as whole-plant CBD-rich cannabis, which includes hundreds of medicinally active components. Whether synthesized in a lab or heavily refined from industrial hemp paste, “pure CBD” products lack the full array of medicinal terpenes and minor phytocannabinoids found in marijuana. These compounds interact with CBD and THC to create what scientists refer to as an “entourage” or “ensemble” effect, so that the therapeutic impact of the whole plant is greater than the sum of its parts.
It’s not that single-molecule CBD won’t work—pure CBD might be helpful in certain cases, but whole-plant CBD has a much wider therapeutic window than CBD as an isolate. This was underscored in a 2015 experiment by Israeli scientists, who found that single-molecule CBD required a much higher dose to be effective compared to whole-plant CBD-rich oil. Moreover, if one missed the mark slightly—either too high or too low—then single-molecule CBD had little impact on pain and inflammation, unlike whole-plant CBD-rich oil, which was effective at a much lower and broader dosage range. Problematic interactions with other drugs are also more likely with high doses of single-molecule CBD.
“The therapeutic synergy observed with plant extracts results in the requirement for a lower amount of active components, with consequent reduced adverse effects,” the Israeli researchers concluded. Other scientists have reported similar findings.
CBD is a mighty molecule, to be sure—but the whole plant is mightier.
Martin A. Lee is the director of Project CBD and the author of several books, including Smoke Signals: A Social History of Marijuana and Acid Dreams: The Complete Social History of LSD: The CIA, the Sixties, and Beyond.
Unlicensed Marijuana Dispensaries in Michigan May Continue to Operate Due To Shortage
Prosecutors in Nebraska Will Dismiss Case Against CBD Store Owners
Governor of New York Presents Plan to Legalize Recreational Marijuana
Amir K. Went All-In on His Dreams and is Now One of L.A.’s Adored Comedians
Laws7 days ago
Vermont Supreme Court Rules Marijuana Smell is Not Grounds for Search
Health5 days ago
Medical Marijuana Recalled From Two Michigan Dispensaries Due to Failed Lab Tests
News6 days ago
Alexandria Ocasio-Cortez Brings Former Marijuana Policy Project Director to Her Staff
People5 days ago
Antonio Bascaro: Father. War Hero. Longest Living Pot Prisoner
Legalization6 days ago
Rep. Earl Blumenauer Introduces Bill to Regulate Cannabis Like Alcohol
News7 days ago
Report: Illicit Pot is Almost 50 Percent Cheaper Than That Bought Legally in Canada
Medical Marijuana5 days ago
NJ Doctor Suspended for Recommending Medical Marijuana to Thousands of Patients
Sponsored6 days ago
What are the Best Strains from Humboldt to Grow Outdoors?